Overview

Doxycycline for Lateral Elbow Tendinopathy

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the feasibility of subantimicrobial -dose (SD) doxycycline to improve outcomes of nonsurgical management of lateral elbow tendinopathy via matrix metalloproteinase (MMP) inhibition as well as evaluate if participants will be compliant to with prescribed medication and exercise treatment. Our working hypothesis is that patients with lateral elbow tendinopathy will be receptive to treatment with SD-doxycycline and compliant with the prescribed treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Hospital for Special Surgery, New York
Treatments:
Doxycycline